Surgery is the most important treatment for PMP. In the past, biopsy, (repeated) tumor reduction, combined with systemic chemotherapy and (or) intraperitoneal chemotherapy were mainly adopted. Although the surgical procedure was simple and less invasive, patients were prone to recurrence after operation, and the clinical efficacy was poor[14,15,16]。 1980 Spratt et al.[17]Tumor cytoreductive surgery (CRS) plus intraperitoneal hyperthermia infusion chemotherapy (HIPEC) was introduced for the first time, which provided a new idea for PMP treatment. 2001 Sugarbaker[18]CRS + HIPEC + early postoperative intraperitoneal chemotherapy (EIPC) was systematically studied, proving that this therapy is the best strategy for PMP. In 2008, PSOGI reached an expert consensus on CRS + HIPEC treatment for PMP[16]。 2012 Chua et al.[19]A detailed analysis of 2,298 PMP treatment data in multicenters worldwide showed that standardized CRS + HIPEC can prolong overall Survival (OS) by 196 months (16.3 years) and Progression Free Survival (PFS) by 98 months (8.2 years), with a 10-year Survival rate of 63% and a 15-year Survival rate of 59%. Due to these outstanding efficacies, in 2014, PSOGI held the 9th International Peritoneal Cancer Congress in the Netherlands and officially recommended CRS + HIPEC as the standard treatment for PMP[20]。